Sean D Sullivan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10520587/publications.pdf

Version: 2024-02-01

109264 175177 12,115 53 35 52 citations h-index g-index papers 53 53 53 14131 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Pharmacists as health care providers: Lessons from California and Washington. JACCP Journal of the American College of Clinical Pharmacy, 2018, 1, 39-44.	0.5	9
2	Toward a Hedonic Value Framework in Health Care. Value in Health, 2017, 20, 261-265.	0.1	8
3	Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults. Dermatology and Therapy, 2017, 7, 493-505.	1.4	32
4	Epidural Corticosteroid Injections for Radiculopathy and Spinal Stenosis. Annals of Internal Medicine, 2015, 163, 373-381.	2.0	146
5	Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report. Value in Health, 2015, 18, 161-172.	0.1	539
6	An epidemiologic model to project the impact of changes in glomerular filtration rate on quality of life and survival among persons with chronic kidney disease. International Journal of Nephrology and Renovascular Disease, 2014, 7, 271.	0.8	8
7	Mapping a Patient-Reported Functional Outcome Measure to a Utility Measure for Comparative Effectiveness and Economic Evaluations in Older Adults with Low Back Pain. Medical Decision Making, 2014, 34, 873-883.	1.2	7
8	Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value in Health, 2014, 17, 5-14.	0.1	742
9	Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios. Value in Health, 2014, 17, 525-536.	0.1	41
10	Trends in cost and outcomes among adult and pediatric patients with asthma: 2000–2009. Annals of Allergy, Asthma and Immunology, 2013, 111, 516-522.	0.5	46
11	A Systematic Review to Assess Comparative Effectiveness Studies in Epidural Steroid Injections for Lumbar Spinal Stenosis and to Estimate Reimbursement Amounts. PM and R, 2013, 5, 705-714.	0.9	32
12	Study protocol: The back pain outcomes using longitudinal data (BOLD) registry. BMC Musculoskeletal Disorders, 2012, 13, 64.	0.8	45
13	Asthma outcomes: Healthcare utilization and costs. Journal of Allergy and Clinical Immunology, 2012, 129, S49-S64.	1.5	88
14	CAN WE RELIABLY BENCHMARK HEALTH TECHNOLOGY ASSESSMENT ORGANIZATIONS?. International Journal of Technology Assessment in Health Care, 2012, 28, 159-165.	0.2	30
15	EBM, HTA, and CER: Clearing the Confusion. Milbank Quarterly, 2010, 88, 256-276.	2.1	140
16	Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations?. International Journal of Technology Assessment in Health Care, 2010, 26, 71-78.	0.2	52
17	Health technology assessment for resource allocation decisions: Are key principles relevant for Latin America?. International Journal of Technology Assessment in Health Care, 2010, 26, 421-427.	0.2	31
18	Impact of asthma control on sleep, attendance at work, normal activities, and disease burden. Annals of Allergy, Asthma and Immunology, 2010, 105, 118-123.	0.5	49

#	Article	IF	Citations
19	An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 59-99.	2.5	1,591
20	Key principles for the improved conduct of health technology assessments for resource allocation decisions. International Journal of Technology Assessment in Health Care, 2008, 24, 244-258.	0.2	356
21	Expenditures and Health Status Among Adults With Back and Neck Problems. JAMA - Journal of the American Medical Association, 2008, 299, 656.	3.8	1,291
22	Agreement between Caregiver Reported Healthcare Utilization and Administrative Data for Children with Asthma. Journal of Asthma, 2007, 44, 189-194.	0.9	15
23	Cost-effectiveness of peginterferon \hat{l} ±-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom. European Journal of Gastroenterology and Hepatology, 2007, 19, 631-638.	0.8	18
24	International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet, The, 2007, 370, 741-750.	6.3	1,818
25	Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B. Pharmacoeconomics, 2007, 25, 963-977.	1.7	42
26	Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practicesâ€"Budget Impact Analysis. Value in Health, 2007, 10, 336-347.	0.1	517
27	Economic Evaluation in the US. Pharmacoeconomics, 2006, 24, 1163-1168.	1.7	27
28	Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study. Pediatric Allergy and Immunology, 2006, 17, 21-27.	1.1	31
29	Practice-Level Effects of Interventions to Improve Asthma Care in Primary Care Settings: The Pediatric Asthma Care Patient Outcomes Research Team. Health Services Research, 2005, 40, 1737-1757.	1.0	37
30	A Multisite Randomized Trial of the Effects of Physician Education and Organizational Change in Chronic Asthma Care. JAMA Pediatrics, 2005, 159, 428.	3.6	62
31	Daily versus As-Needed Corticosteroids for Mild Persistent Asthma. New England Journal of Medicine, 2005, 352, 1519-1528.	13.9	363
32	The Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and Design. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2005, 2, 277-283.	0.7	256
33	The burden of uncontrolled asthma on the U.S. health care system. Managed Care, 2005, 14, 4-7; discussion 25-7.	0.3	16
34	The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes. Annals of Allergy, Asthma and Immunology, 2004, 93, 538-545.	0.5	50
35	Global Epidemiology of Hepatitis B Virus. Journal of Clinical Gastroenterology, 2004, 38, S158-S168.	1.1	489
36	Resource costs for asthma-related care among pediatric patients in managed care. Annals of Allergy, Asthma and Immunology, 2003, 91, 251-257.	0.5	46

#	Article	IF	Citations
37	Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. Journal of Allergy and Clinical Immunology, 2003, 112, 1229-1236.	1.5	69
38	Rapid Magnetic Resonance Imaging vs Radiographs for Patients With Low Back Pain. JAMA - Journal of the American Medical Association, 2003, 289, 2810.	3.8	311
39	Vascular Catheter Site Care: The Clinical and Economic Benefits of Chlorhexidine Gluconate Compared with Povidone Iodine. Clinical Infectious Diseases, 2003, 37, 764-771.	2.9	81
40	Cost Effectiveness of Lung-Volume–Reduction Surgery for Patients with Severe Emphysema. New England Journal of Medicine, 2003, 348, 2092-2102.	13.9	218
41	Introduction. Journal of Managed Care Pharmacy, 2003, 9, 2-2.	2.2	3
42	Asthma in the United States: Recent Trends and Current Status. Journal of Managed Care Pharmacy, 2003, 9, 3-7.	2.2	28
43	The cost-effectiveness of an inner-city asthma intervention for children. Journal of Allergy and Clinical Immunology, 2002, 110, 576-581.	1.5	129
44	Health Economics. , 2002, , 657-671.		2
45	The health economics of asthma and rhinitis. I. Assessing the economic impact. Journal of Allergy and Clinical Immunology, 2001, 107, 3-8.	1.5	490
46	Health economics of asthma and rhinitis. II. Assessing the value of interventions. Journal of Allergy and Clinical Immunology, 2001, 107, 203-210.	1.5	43
47	Economic analysis of lung volume reduction surgery as part of the national emphysema treatment trial. Annals of Thoracic Surgery, 2001, 71, 995-1002.	0.7	28
48	Design and Analytic Considerations in Determining the Cost-Effectiveness of Early Intervention in Asthma from a Multinational Clinical Trial. Contemporary Clinical Trials, 2001, 22, 420-437.	2.0	23
49	The Economic Burden of COPD. Chest, 2000, 117, 5S-9S.	0.4	507
50	Trends in the cost of illness for asthma in the United States, 1985-1994. Journal of Allergy and Clinical Immunology, 2000, 106, 493-499.	1.5	328
51	Efficacy of Antiseptic-Impregnated Central Venous Catheters in Preventing Catheter-Related Bloodstream Infection. JAMA - Journal of the American Medical Association, 1999, 281, 261.	3.8	514
52	On the use of survival analysis techniques to estimate medical care costs. Journal of Health Economics, 1999, 18, 365-380.	1.3	89
53	The economic burden of asthma in US children: Estimates from the National Medical Expenditure Surveyâ^†â^†â^ta^ Journal of Allergy and Clinical Immunology, 1999, 104, 957-963.	1.5	182